Patents by Inventor Richard J. Jones

Richard J. Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patella drill guide and trial surgical instrument
    Patent number: 11925365
    Abstract: An orthopaedic surgical instrument includes a patella trial and drill guide that may be used to both perform a surgical trial of the patellofemoral joint and guide the surgeon in drilling a number of anchor holes in the patella of the patient.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: March 12, 2024
    Assignee: DePuy Ireland Unlimited Company
    Inventors: Matthew S. Wallace, Jennifer B. Wyant, Richard S. Jones, David S. Barrett, Michael J. Rock, Abraham P. Wright, Olen J. Borkholder, Robert S. Gorab, Rusty T. Meier
  • USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20230310354
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Application
    Filed: April 28, 2023
    Publication date: October 5, 2023
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
    Patent number: 11648222
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: May 16, 2023
    Assignees: IO Therapeutics, Inc., The Johns Hopkins Univercity
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • MONOCLONAL ANTIBODIES TARGETING HSP70 AND THERAPEUTIC USES THEREOF
    Publication number: 20230128075
    Abstract: Provided herein are agents, such as antibodies and chimeric antigen receptors, that target HSP70. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an HSP70-targeting agent. The HSP70-specific antibody may enhance uptake of HSP70 by antigen presenting cells.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 27, 2023
    Applicants: Board of Regents, The University of Texas System, Asylia Therapeutics
    Inventors: Robert Z. ORLOWSKI, Richard J. JONES, Laura C. BOVER, Jeno GYURIS, John MILLER, James Bernard McCLORY, Darragh MAC CANN, William M. WINSTON, SR.
  • USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20220184013
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Application
    Filed: March 3, 2022
    Publication date: June 16, 2022
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20210137865
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Application
    Filed: December 28, 2020
    Publication date: May 13, 2021
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20210137866
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Application
    Filed: December 29, 2020
    Publication date: May 13, 2021
    Inventors: Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna
  • Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
    Patent number: 10940127
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: March 9, 2021
    Assignees: Io Therapeutics, Inc., The Johns Hopkins University
    Inventors: Gabriel Ghiaur, Richard J. Jones, Alonso Salvador, Roshantha A. Chandraratna
  • USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20180333380
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Application
    Filed: November 23, 2016
    Publication date: November 22, 2018
    Inventors: Gabriel Ghiaur, Richard J. Jones, Alonso Salvador, Roshantha A. Chandraratna
  • Cyclophosphamide in combination with immune therapeutics
    Patent number: 9539267
    Abstract: The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug, either alone, or in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: January 10, 2017
    Assignee: The Johns Hopkins University
    Inventors: Robert A. Brodsky, Richard J. Jones, Richard F. Ambinder
  • Method of identifying patients not suitable for high-dose cyclophosphamide treatment
    Patent number: 9279803
    Abstract: The present invention provides methods of identifying subjects that are suitable and not suitable for high-dose cyclophosphamide treatment.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: March 8, 2016
    Assignees: The Johns Hopkins University, Accentia Biopharmaceuticals, Inc.
    Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, Jr., Susan Bonitz, Adam Kaplin, Carlos Santos
  • Finger biometric sensor including laterally adjacent piezoelectric transducer layer and associated methods
    Patent number: 9092653
    Abstract: A finger biometric sensor may include a finger biometric sensing layer having an upper major surface and at least one sidewall surface adjacent thereto. The finger biometric layer may be for generating signals related to at least one biometric characteristic of the user's finger when positioned adjacent the first major surface. The finger biometric sensor may also include a piezoelectric transducer layer coupled to the at least one sidewall surface of the finger biometric sensing layer and a plurality of electrically conductive layers coupled to the piezoelectric transducer layer to define transducer electrodes. At least one of the electrically conductive layers may also cooperate with the finger biometric sensing layer for sensing the at least one biometric characteristic.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: July 28, 2015
    Assignee: APPLE INC.
    Inventors: Dale R. Setlak, James Warren Neil, Daryl D. Williams, Richard J. Jones, Nicolaas W. Van Vonno
  • Methods for detecting and monitoring circulating cancer stem cells
    Patent number: 8748113
    Abstract: Provided herein are compositions, methods, and kits useful for detecting whether a subject has or is likely to develop a cancer and for monitoring, staging and examining a cancer patient. Also provide herein are methods for screening compounds.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: June 10, 2014
    Assignee: The Johns Hopkins University
    Inventors: William Matsui, Richard J. Jones, Carol A. Huff
  • FINGER BIOMETRIC SENSOR INCLUDING LATERALLY ADJACENT PIEZOELECTRIC TRANSDUCER LAYER AND ASSOCIATED METHODS
    Publication number: 20140105469
    Abstract: A finger biometric sensor may include a finger biometric sensing layer having an upper major surface and at least one sidewall surface adjacent thereto. The finger biometric layer may be for generating signals related to at least one biometric characteristic of the user's finger when positioned adjacent the first major surface. The finger biometric sensor may also include a piezoelectric transducer layer coupled to the at least one sidewall surface of the finger biometric sensing layer and a plurality of electrically conductive layers coupled to the piezoelectric transducer layer to define transducer electrodes. At least one of the electrically conductive layers may also cooperate with the finger biometric sensing layer for sensing the at least one biometric characteristic.
    Type: Application
    Filed: December 17, 2013
    Publication date: April 17, 2014
    Inventors: DALE R. SETLAK, JAMES WARREN NEIL, DARYL D. WILLIAMS, RICHARD J. JONES, NICOLAAS W. VAN VONNO
  • Cyclophosphamide in combination with anti-idiotypic vaccines
    Patent number: 8673321
    Abstract: The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, an autologous idiotypic vaccine and monoclonal antibodies that selectively bind B-cell specific antigens.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: March 18, 2014
    Assignees: The Johns Hopkins University, Accentia Biopharmaceuticals, Inc.
    Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, Jr., Susan Bonitz, Carlos Santos
  • Finger biometric sensor including laterally adjacent piezoelectric transducer layer and associated methods
    Patent number: 8618910
    Abstract: A finger biometric sensor may include a finger biometric sensing layer having an upper major surface and at least one sidewall surface adjacent thereto. The finger biometric layer may be for generating signals related to at least one biometric characteristic of the user's finger when positioned adjacent the first major surface. The finger biometric sensor may also include a piezoelectric transducer layer coupled to the at least one sidewall surface of the finger biometric sensing layer and a plurality of electrically conductive layers coupled to the piezoelectric transducer layer to define transducer electrodes. At least one of the electrically conductive layers may also cooperate with the finger biometric sensing layer for sensing the at least one biometric characteristic.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: December 31, 2013
    Assignee: Authentec, Inc.
    Inventors: Dale R. Setlak, James W. Neil, Daryl D. Williams, Richard J. Jones, Nicolaas W. Van Vonno
  • Finger biometric sensor including laterally adjacent piezoelectric transducer layer and associated methods
    Patent number: 8604905
    Abstract: A finger biometric sensor may include a finger biometric sensing layer having an upper major surface and at least one sidewall surface adjacent thereto. The finger biometric layer may be for generating signals related to at least one biometric characteristic of the user's finger when positioned adjacent the first major surface. The finger biometric sensor may also include a piezoelectric transducer layer coupled to the at least one sidewall surface of the finger biometric sensing layer and a plurality of electrically conductive layers coupled to the piezoelectric transducer layer to define transducer electrodes. At least one of the electrically conductive layers may also cooperate with the finger biometric sensing layer for sensing the at least one biometric characteristic.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: December 10, 2013
    Assignee: Authentec, Inc.
    Inventors: Dale R. Setlak, James W. Neil, Daryl D. Williams, Richard J. Jones, Nicolaas W. Van Vonno
  • Cyclophosphamide in Combination with Anti-Idiotypic Vaccines
    Publication number: 20120148611
    Abstract: The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug in combination with immune therapeutics such as, for example, an autologous idiotypic vaccine and monoclonal antibodies that selectively bind B-cell specific antigens.
    Type: Application
    Filed: September 12, 2011
    Publication date: June 14, 2012
    Applicants: Accentia Biopharmaceuticals, inc., The Johns Hopkins University
    Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, JR., Susan Bonitz, Carlos Santos
  • USE OF HIGH-DOSE, POST-TRANSPLANTATION OXAZAPHOSPHORINE DRUGS FOR REDUCTION OF TRANSPLANT REJECTION
    Publication number: 20120148577
    Abstract: A lymphocytotoxic, but hematopoietic stem cell-sparing, high-dose amount of an oxazaphosphorine drug such as, for example, cyclophosphamide, administered post-transplantation can be used to reduce transplant rejection, including graft-versus-host-disease (GVHD). In some embodiments, the transplants are bone marrow transplants or hematopoietic stem cell transplants carried out for the treatment of hematologic disorders, including hematologic malignancies and non-malignant hematologic disorders. In some embodiments, the transplants are carried out for the treatment of hereditary hemoglobinopathies, such as sickle cell anemia and thalassemia.
    Type: Application
    Filed: October 13, 2011
    Publication date: June 14, 2012
    Applicants: ACCENTIA BIOPHARMACEUTICALS, INC., JOHNS HOPKINS UNIVERSITY
    Inventors: EPHRAIM J. FUCHS, LEO LUZNIK, ROBERT A. BRODSKY, RICHARD J. JONES, FRANCIS E. O'DONNELL, JR., CARLOS SANTOS, SUSAN BONITZ
  • METHOD OF IDENTIFYING PATIENTS SUITABLE FOR HIGH-DOSE CYCLOPHOSPHAMIDE TREATMENT
    Publication number: 20120129206
    Abstract: The present invention provides methods of identifying subjects that are suitable for high-dose cyclophosphamide treatment.
    Type: Application
    Filed: September 22, 2011
    Publication date: May 24, 2012
    Applicants: Accentia Biopharmaceuticals, Inc., The Johns Hopkins University
    Inventors: Robert A. Brodsky, Richard J. Jones, Francis E. O'Donnell, JR., Susan Bonitz, Adam Kaplin, Carlos Santos